NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, highlighted the efficacy of its lead drug, NV-387 against a range of viruses in animal models as it prepares to begin f...
NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, believes its drug NV-387 could be crucial in fighting the bird flu virus H5N1. In recent studies, NV-387 outperformed t...
SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-br...
NanoViricides (NYSE-A:NNVC) announced that its ultra-broad-spectrum antiviral drug candidate NV-387 demonstrated effectiveness in protecting lungs from damage from Influenza A H3N2 in a lethally infe...
NanoViricides (NYSE-A:NNVC) said its lead antiviral candidate, NV-387, was found to be highly active when taken orally, making potentially the first nanomedicine to be effective in this way. NV-387...
NanoViricides (NYSE-A:NNVC) has unveiled additional positive data for its lead clinical-stage broad-spectrum antiviral agent NV-387, a desirable blood concentration profile that it believes could ena...
NanoViricides (NYSE-A:NNVC) is developing a first-in-class, broad-spectrum anti-viral agent NV-387 that it believes could revolutionize the treatment of viral infections including RSV, COVID, and infl...
NanoViricides (NYSE-A:NNVC) announced that it has engaged Chicago-based life sciences consultancy firm Aagami for business development, specifically to seek out licensing and partnering opportunities ...
NanoViricides (NYSE-A:NNVC) announced that it has engaged Chicago-based life sciences consultancy firm Aagami for business development, specifically to seek out licensing and partnering opportunities ...
NanoViricides (NYSE-A:NNVC) has been awarded a ‘Buy' rating and $6.50 price target by analysts at EF Hutton following the release of positive data on the anti-influenza A/H3N2 activity of its therap...
NanoViricides (NYSE-A:NNVC) has been awarded a ‘Buy' rating and $6.50 price target by analysts at EF Hutton following the release of positive data on the anti-influenza A/H3N2 activity of its therap...